Editing Integrase (section)

=== Antiretroviral therapy ===
In November 2005, data from a [[Clinical trial|phase 2 study]] of an investigational HIV [[integrase inhibitor]], [[MK-0518]], demonstrated that the compound has potent antiviral activity. On October 12, 2007, the Food and Drug Administration (U.S.) approved the integrase inhibitor [[Raltegravir]] (MK-0518, brand name Isentress). The second integrase inhibitor, [[elvitegravir]], was approved in the U.S. in August 2012.